-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $564

Benzinga·12/05/2025 15:31:41
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $516 to $564.